BDX vs MDLN stock comparison
Becton Dickinson & vs. Medline · data as of November 13, 2026
Becton Dickinson & (BDX) has a market value of about $59.4B, Medline (MDLN) about $51.9B. Over their latest twelve months Becton Dickinson & had revenue of $19.5B and Medline $30.7B.
On our five checks Becton Dickinson & scores higher: 2.0 out of 5 (weak) against 1.0 (weak).
By area, the stronger company is Becton Dickinson & on track record; Becton Dickinson & on shareholder returns.
Becton Dickinson & is cheaper on earnings (P/E 43.1 vs. 89.7).
Becton Dickinson & leads on 14 of the compared lines and Medline on 5.
Side by side
| BDX | MDLN | |
|---|---|---|
| Size and price | ||
| Market cap | $59.4B | $51.9B |
| Share price | $218.03 | $39.47 |
| Score | ||
| Overall score (of 5) | 2.0 | 1.0 |
| Value | 0 | 0 |
| Future growth | 2 | 2 |
| Track record | 2 | 0 |
| Financial health | 2 | 2 |
| Shareholder returns | 4 | 1 |
| Valuation | ||
| P/E (TTM) | 43.1 | 89.7 |
| Forward P/E | 17.5 | 26.2 |
| Price / free cash flow | 22.0 | 27.4 |
| Price / sales | 3.1 | 1.7 |
| EV / EBITDA | 14.3 | 22.6 |
| PEG | 2.61 | — |
| DCF value vs. price | −41% | −48% |
| Business | ||
| Revenue | $19.5B | $30.7B |
| Net income | $1.1B | $566M |
| Free cash flow | $2.7B | $1.9B |
| Net margin | 5.9% | 1.8% |
| Gross margin (5-yr avg.) | 44.6% | 26.4% |
| ROIC (5-yr avg.) | 4.8% | 8.6% |
| Growth | ||
| Revenue growth (1 yr) | 8.2% | 11.5% |
| Revenue growth (5 yrs, per year) | 6.3% | — |
| EPS growth (5 yrs, per year) | 16.5% | — |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$16.1B | -$9.1B |
| Dividend yield | 1.94% | None |
| Shareholder yield | 3.6% | 0.1% |
| Analysts | ||
| Upside to average target | +4% | +15% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: BDX TTM to September 30, 2026, MDLN TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Becton Dickinson & or Medline?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Becton Dickinson & scores 2.0 out of 5 and Medline 1.0; the table shows where each one is stronger.
Is Becton Dickinson & cheaper than Medline?
On trailing earnings, Becton Dickinson & trades at a P/E of 43.1 and Medline at 89.7, so Becton Dickinson & is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which pays a higher dividend?
Becton Dickinson & yields 1.94% and Medline nothing (no dividend).
Full Becton Dickinson & analysis → Full Medline analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.